Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Feb;25(2):171-6.
doi: 10.1111/jce.12302. Epub 2013 Oct 30.

Cardiac sarcoidosis: electrophysiological outcomes on long-term follow-up and the role of the implantable cardioverter-defibrillator

Amr Mohsen  1 , Alejandro Jimenez, Robert E Hood, Timm Dickfeld, Anastasios Saliaris, Stephen Shorofsky, Magdi M Saba
Affiliations
Clinical Trial

Cardiac sarcoidosis: electrophysiological outcomes on long-term follow-up and the role of the implantable cardioverter-defibrillator

Amr Mohsen et al. J Cardiovasc Electrophysiol. 2014 Feb.

Abstract

Objectives: The objectives of this study were to identify the predictors of life-threatening ventricular arrhythmias in patients with cardiac sarcoidosis (CS) and to evaluate the role of the implantable cardioverter-defibrillator (ICD) in this patient population.

Background: ICD implantation is a class IIA recommendation for patients with CS. However, some indications for ICD implantation in CS patients are still unclear and not enough data are available to establish predictors of malignant ventricular tachyarrhythmias in this group of patients.

Methods: We retrospectively identified all consecutive patients who were diagnosed with CS, during the period from March 2002 to April 2010. Cardiac rhythm devices were regularly interrogated and clinical data recorded during follow-up visits.

Results: Thirty-three patients (17 male) with CS were identified. The mean age was 53 ± 11. The mean left ventricular ejection fraction (LVEF) was 41 ± 18%. Thirty patients received an ICD. Twelve patients (36.3%) had sustained ventricular arrhythmias. Eleven patients received appropriate therapies and 9 patients received inappropriate shocks, representing 36.7% and 30.0% of the ICD population, respectively. Patients who received appropriate ICD therapies were younger with mean age 47.4 ± 7.8, and had a lower mean LVEF 33.0 ± 12.0 compared to those who did not receive ICD therapies (P = 0.0301 and 0.0341, respectively). There were no other demographic, clinical, electrocardiographic, electrophysiological, or imaging markers that predicted the future occurrence of appropriate ICD therapies in our cohort of patients.

Conclusions: CS is strongly associated with malignant ventricular arrhythmias. No specific predictors of such tachyarrhythmias emerged, other than young age and low LVEF.

Keywords: cardiac sarcoid; implantable cardioverter-defibrillator; sarcoidosis; sudden cardiac death; ventricular tachycardia.

PubMed Disclaimer

Comment in

  • Arrhythmia in cardiac sarcoidosis.
    Porterfield CP, Ferguson JD. Porterfield CP, et al. J Cardiovasc Electrophysiol. 2014 Feb;25(2):177-8. doi: 10.1111/jce.12333. J Cardiovasc Electrophysiol. 2014. PMID: 25763448 No abstract available.

Publication types

MeSH terms

LinkOut - more resources